DOI QR코드

DOI QR Code

Can Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low-Emetogenic Chemotherapy?

  • Published : 2013.01.31

Abstract

Background: The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea and vomiting (CINV) among patients receiving low emetogenic chemotherapy (LEC) with and without granisetron injection as the primary prophylaxis in addition to dexamethasone and metochlopramide. Materials and Methods: This was a single-centre, prospective cohort study. A total of 96 patients receiving LEC (52 with and 42 without granisetron) were randomly selected from the full patient list generated using the e-Hospital Information System (e-His). The rates of complete control (no CINV from days 1 to 5) and complete response (no nausea or vomiting in both acute and delayed phases) were identified through patient diaries which were adapted from the MASCC Antiemesis Tool (MAT). Selected covariates including gender, age, active alcohol consumption, morning sickness and previous chemotherapy history were controlled using the multiple logistic regression analyses. Results: Both groups showed significant difference with LEC regimens (p<0.001). No differences were found in age, gender, ethnic group and other baseline characteristics. The granisetron group indicated a higher complete response rate in acute emesis (adjusted OR: 0.1; 95%CI 0.02-0.85; p=0.034) than did the non-granisetron group. Both groups showed similar complete control and complete response rates for acute nausea, delayed nausea and delayed emesis. Conclusions: Granisetron injection used as the primary prophylaxis in LEC demonstrated limited roles in CINV control. Optimization of the guideline-recommended antiemetic regimens may serve as a less costly alternative to protect patients from uncontrolled acute emesis.

References

  1. Molassiotis A, Coventry PA, Stricker CT, et al (2007). Validation and psychometric properties of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symp Manage, 34, 148-59. https://doi.org/10.1016/j.jpainsymman.2006.10.018
  2. Mulders M, Vingerhoets A, Breed W, et al (2008). The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nursing, 12, 97-102. https://doi.org/10.1016/j.ejon.2007.10.002
  3. Pharmacy Services Division Malaysia (2011). Drug Formulary. Ministry of Health, Kuala Lumpur pp 37.
  4. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8. https://doi.org/10.1002/cncr.11433
  5. Rigacci L, Landi C, Caruso JP, et al (2011). Single dose palanosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin lymphoma patients. Leukemia Res, 36, 182-5.
  6. Saito M, Aogi K, Sekine I, et al (2009). Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy. Lancet Oncol, 10, 115-24. https://doi.org/10.1016/S1470-2045(08)70313-9
  7. Schnell FM (2003). Chemotherapy induced nausea and vomiting: the importance of acute antiemetic control. Oncologist, 8, 187-98. https://doi.org/10.1634/theoncologist.8-2-187
  8. Schwartzberg LS, Jacobs P, Matsouka P, et al (2011). The role of second-generation 5-HT3 antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies. Crtical Review Oncol Hemato, 83, 59-70.
  9. Smith JA, Anastasia P, Rappaport M (2012). Prevention and treatment of chemotherapy-induced nausea and vomiting with the granisetron transdermal system: three clinical perspectives on three case studies in solid tumors. J Supp Oncol, 10, 1-10. https://doi.org/10.1016/j.suponc.2011.07.002
  10. Vermeulen LC, Windisch PA, Rydman RJ, et al (2000). Using a multihospital systems framework to evaluate and establish drug use policy. J Med Syst, 24, 235-46. https://doi.org/10.1023/A:1005501914725
  11. Dranitsaris G, Bouganim N, Milano C (2012). Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. J Supp Oncol, 20, 1-7.
  12. Ettinger DS, Armstrong DK, Barbour S (2012). Antiemesis. JNCCN, 10, 456-85.
  13. Foubert J, Vaessen G (2005). Nausea: the neglected symptom? Eur J Oncol Nur, 9, 21-3. https://doi.org/10.1016/j.ejon.2004.03.006
  14. Gralla RJ, Roila F, Tonato M, et al (2005). The 2004 perusia antiemetic consensus guideline process: methods, procedures, and participants. Supp Care Cancer, 13, 77-9. https://doi.org/10.1007/s00520-004-0756-5
  15. Grunberg SM, Deuson RR, Mavros P, et al (2004). Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer, 100, 2261-8. https://doi.org/10.1002/cncr.20230
  16. Giuliani F, Gilenti G, Nugnes I, et al (2008). Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer patients. EJC Supp, 6, 102-6.
  17. Hassan BAR, Yusoff ZBH (2010). Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
  18. Herrstedt J (2002). Nausea and emesis: still an unsolved problem in cancer patients? Supp Care Cancer, 10, 85-7. https://doi.org/10.1007/s00520-001-0339-7
  19. Hensley ML, Hagerty KL, Kewalramani T, et al (2009). American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol, 27, 127-45.
  20. Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol, 21, 4112-9. https://doi.org/10.1200/JCO.2003.01.095
  21. Hesketh PJ, Morrow G, Komorowski AW, et al (2012). Efficacy and safety of palanosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low-emetogenic chemotherapy. Supp Care Cancer, 20, 2633-7. https://doi.org/10.1007/s00520-012-1527-3
  22. Hofman M, Morrow GR, Roscoe JA, et al (2004). Cancer patients’ expectations of experiencing treatment-related side effects. Cancer, 101, 851-7. https://doi.org/10.1002/cncr.20423
  23. Ismail F, Mohamed AK, Lim KH (2011). Systemic therapy of cancer, 2nd edition. Ministry of Health, Kuala Lumpur pp 75-8.
  24. Jordan K, Schmoll HJ, Aapro MS (2007). Comparative activity of antiemetic drugs. Oncol Hemato, 61, 162-75.
  25. Koeller JM, Aapro MS, Gralla RJ, et al. (2002) Antiemetic guidelines: creating a more practical treatment approach. Supp Care Cancer, 10, 519-22. https://doi.org/10.1007/s00520-001-0335-y
  26. Kris MG, Hesketh PJ, Herrstedt J, et al (2005). Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supp Care Cancer, 13, 85-96. https://doi.org/10.1007/s00520-004-0699-x
  27. Almazron S, Alnaim L (2012). Evaluation of adherence to chemotherapy-induced nausea and vomiting guidelines. An observational study. J Cancer Therapy, 3, 613-20. https://doi.org/10.4236/jct.2012.35078
  28. Barrajon E, de las Penas R (2000). Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis. Supp Care Cancer, 8, 323-33. https://doi.org/10.1007/s005209900120
  29. Bourdeanu L, Frankel P, Yu W, et al (2012). Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy. J Supp Oncol, 10, 149-54. https://doi.org/10.1016/j.suponc.2011.10.007
  30. Brigitte BD, Robert R, Panagiotis M, et al (2006). Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol, 24, 4472-8. https://doi.org/10.1200/JCO.2006.05.6382
  31. Burmeister H, Achi S, Studer C, et al (2012). Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Supp Care Cancer, 20, 141-7. https://doi.org/10.1007/s00520-010-1079-3
  32. del Giglio A, Soares HP, Caparroz C, et al (2000). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer, 89, 2301-8. https://doi.org/10.1002/1097-0142(20001201)89:11<2301::AID-CNCR19>3.0.CO;2-6

Cited by

  1. Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
  2. Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome vol.16, pp.1, 2015, https://doi.org/10.1186/s40360-015-0005-1
  3. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis vol.43, pp.4, 2015, https://doi.org/10.1080/21548331.2015.1077095
  4. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential vol.25, pp.1, 2017, https://doi.org/10.1007/s00520-016-3391-z
  5. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting vol.25, pp.9, 2017, https://doi.org/10.1007/s00520-017-3679-7
  6. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients pp.1433-7339, 2018, https://doi.org/10.1007/s00520-018-4464-y